News and Trends 6 Feb 2018
Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates
AstraZeneca has given up on the development of its PD-1 checkpoint inhibitor drug, which was the headline act when its subsidiary MedImmune acquired Amplimmune in 2013. There was no sentiment as pharma giant AstraZeneca cut a number of drugs from its pipeline after they did not perform as expected during clinical trials. The biggest name to get […]